Trevi Therapeutics, Inc. (TRVI): Insider Trading, Congress Trades & Research | Tormere

TRVI

$13.26-5.18%visit website

Trevi Therapeutics, Inc.

Market Cap

$1.9B

Live price × SEC shares (Jul 31, 2026)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

1.09

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

5.9

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	10,085	6,193	9,941	15,152	41,371
Total operating expenses	13,916	10,220	14,912	20,509	59,557
Operating income	(13,916)	(10,220)	(14,912)	(20,509)	(59,557)
Interest expense	0.00	0.00
Pretax income	(11,817)	(8,332)	(13,212)	(17,816)	(51,177)
Income tax	(15.0)	(16.0)	(20.0)	(19.0)	(70.0)
Net income	(11,802)	(8,316)	(13,192)	(17,797)	(51,107)
EPS (basic) ($)	(0.08)		(0.09)	(0.11)	(0.35)
EPS (diluted) ($)	(0.08)		(0.09)	(0.11)	(0.35)
Weighted avg. shares (basic)	145,105		145,593	156,602
Weighted avg. shares (diluted)	145,105		145,593	156,602

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 6, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 30 more quarters, back to Mar 2018, with Tormere Pro.

Signals

Insider Velocity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

Analyst Consensus

Strong Buy

18 analysts

Velocity Score

23.98x

Avg Daily Selling (90d)

437 sh/day

Baseline Daily Selling

0.0 sh/day

Unique Sellers (90d)

1

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-09-15	2026-09-17	Heffernan Michael Thomas	Director	Sale	39.4K	$15.09	$594K	6,351	View

Recent News

(TRVI) Comprehensive Trading Strategy Report (TRVI:CA)

Stock Traders Daily · 2026-11-04

Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026

Yahoo · 2026-11-02

Quarterly results and a company update are on Trevi's Nov. 9 call agenda.

Stock Titan · 2026-11-02

Trevi Therapeutics (TRVI) Stock May Still Look Expensive Against Book Value

Yahoo · 2026-11-01

Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference

Yahoo · 2026-10-27

Do Trevi Therapeutics’ (TRVI) CORAL Data and GSK’s Exit Reframe Its Chronic Cough Ambitions?

Yahoo · 2026-10-13

Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting

Yahoo · 2026-10-13

Trevi Therapeutics Announces Results From Phase 2b CORAL Trial Accepted As Oral Presentation At CHEST 2026 Annual Meeting Of American College Of Chest Physicians

Benzinga · 2026-10-13

Trevi Therapeutics Q2 2026 Earnings Call Transcript

Benzinga · 2026-10-12

Top 4 Healthcare Stocks Backed by Raymond James Analysts

Yahoo · 2026-10-08

Trevi Therapeutics (TRVI) Stock Trades At A Premium To Fair Value

Yahoo Finance · 2026-09-05

Trevi Therapeutics to Participate in Upcoming September Conferences

Yahoo Finance · 2026-09-03

Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

Yahoo Finance · 2026-07-30

Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market

Yahoo Finance · 2026-07-18

Trevi Therapeutics (TRVI) Stock May Be Overvalued Despite Its 5 Year Surge

Simply Wall St · 2026-07-17

Informational purposes only, not investment advice.

Recent Insider Activity (Form 4) — Last 5

Date	Insider	Type	Shares	Value
2026-09-15	Heffernan Michael Thomas	S	18,321	$276,463.89
2026-09-15	Heffernan Michael Thomas	S	100	$1,588
2026-09-15	Heffernan Michael Thomas	S	20,952	$316,165.68